TEL AVIV, Israel & SEATTLE--(BUSINESS WIRE)--VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that it will present preclinical data demonstrating VB-111’s potential synergy and additive therapeutic effect when administered in combination with the conventional chemotherapy cancer treatments. The company will present data demonstrating this synergistic effect in an in vivo preclinical model of metastatic lung cancer at 4:40 p.m. PT today at the 14th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) at the Washington State Convention Center in Seattle.
